Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TWi BiotechnologyROCO:6610 -1.34%31 Buyback Yield % is -3.20 as of Jul. 31, 2026. GuruFocus rates ROCO:6610 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, TWi Biotechnology ranks better than 65.71% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for TWi Biotechnology's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6610 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, TWi Biotechnology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TWi Biotechnology Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TWi Biotechnology's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where TWi Biotechnology's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TWi Biotechnology (ROCO:6610) has a Buyback Yield % of -3.20 as of Jul. 31, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on TWi Biotechnology and its competitors. According to the industry distribution chart, TWi Biotechnology ranks #252 out of 735 companies in the Biotechnology industry, placing it in the top 34.3%.
Is TWi Biotechnology's Buyback Yield % too high?
TWi Biotechnology's current Buyback Yield % is -3.20. Based on the distribution chart, TWi Biotechnology ranks #252 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TWi Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TWi Biotechnology's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TWi Biotechnology ranks #252 out of 735 companies for Buyback Yield %. This puts TWi Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on TWi Biotechnology and its competitors. TWi Biotechnology's current Buyback Yield % is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TWi Biotechnology stock overvalued right now?
TWi Biotechnology (ROCO:6610) has a current Buyback Yield % of -3.20. The current Buyback Yield % is -3.20. TWi Biotechnology's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For TWi Biotechnology (ROCO:6610), the current Buyback Yield % is -3.20 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.
31GF Score
Get the complete analysis for ROCO:6610
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6610 has been successfully added to your 
